Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus PLD in platinum-resistant recurrent ovarian cancer
NCT04348032Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Mar 2018
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in ovarian cancer, sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04348032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04348032.